Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN1840 DDI Study with Celecoxib in Healthy Participants
NCT04526197Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2020
- Primary completion
- Nov 2020
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atn-224 in Wilson disease (WD) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration (Cmax) of Celecoxib, Area Under The Plasma Concentration Versus Time Curve From Time 0 To The Last Quantifiable Concentration (AUCt) of Celecoxib and 1 more. Started Jul 2020; status: completed.
02
Drugs
atn-224
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on NCT04526197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04526197.